Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors

This study is a single-arm early exploratory clinical study. designed to evaluate the safety and tolerability of GT201 in combination with a PD-1 inhibitor for the treatment of advanced head and neck tumor subjects with safety and tolerability, as well as pharmacokinetic characterization and efficacy The study consists of two phases. The study consists of two phases, a dose-escalation phase and a dose-expansion phase.

NCT Number	NCT06190275
Lead Sponsor	Grit Biotechnology Collaborators: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Conditions	HNSCC
Enrollment	32 participants
Start Date	2024-05-12
Primary Completion	2027-04-30 (estimated)
Study Completion	2027-04-30 (estimated)
Updated on ClinicalTrials.gov	2026-04-24